Intuitive Surgical’s Stock Has Fallen Over 25% This Year, but Goldman Sachs Still Recommends Investors Buy Jul 15, 2026 Life Science
Two Overhyped GLP-1 Stocks Present Buying Opportunities on Dips, with Novo Nordisk and Kailera Therapeutics Each Offering Unique Highlights Jul 14, 2026 Life Science
The Market Has Responded Coolly to Vertex’s Multibillion-Dollar Acquisition, but Management’s Track Record and Integration Capabilities Add Confidence to the Deal Jul 14, 2026 Life Science
Core Business Steady Growth Coupled with Acquisition Tailwinds, Vertex Pharmaceuticals Demonstrates Strong Post-Market Momentum Jul 11, 2026 Life Science
Pfizer Could Rewrite the GLP-1 Race — but Its 7% Yield Is Flashing a Warning Jul 10, 2026 Life Science
Incyte and TG Therapeutics Deliver Notable Growth, Drawing Investment Attention to the Biotech Sector Jul 9, 2026 Life Science
Vertex’s $10 Billion Crinetics Acquisition Lands Amid Record Stock High: Time to Buy? Jul 8, 2026 Life Science
Two Healthcare Blue-Chip Stocks Offer Opportunities as Dividends Shine Bright for Pfizer and Bristol-Myers Squibb Jul 8, 2026 Life Science
Biotech Double Winners Outperform the Market, With Fundamental Tailwinds Poised to Sustain Momentum Jul 7, 2026 Life Science
Eli Lilly Stock Hits Record High as Analysts Bullish on Weight-Loss Drug Market Prospects Jul 7, 2026 Life Science
Undervalued Pharma Dividend Plays: PFE Boasts 7.1% Forward Yield, BMY Delivers 4.3% Jul 7, 2026 Life Science
The $10 Billion Acquisition Is Set, as Vertex Pharmaceuticals Bets on a New Blue Ocean in Rare Endocrine Diseases Jul 7, 2026 Life Science
TransMedics Is Betting on Kidney Transplants and European Expansion Despite a 40% Stock Drop in Six Months, Yet Long-Term Prospects Remain Strong Jul 4, 2026 Life Science
